$18.2 million in Period 2 funding will help the progress and scale-up of COVID-19 antigen check based on Simoa® technological know-how
Quanterix Company (NASDAQ: QTRX), a enterprise digitizing biomarker evaluation to advance the science of precision overall health, these days declared that it has entered into a Stage 2 agreement with the Nationwide Institutes of Wellbeing (NIH) as a result of its Quick Acceleration of Diagnostics (RADx℠) initiative. The contract, which has a full award value of $18.2 million, will speed up the ongoing improvement, scale-up and deployment of a novel SARS-CoV-2 antigen test based on Quanterix’ extremely-sensitive Simoa engineering. Preliminary success reveal that the test has the probable to enable detection from a wide range of sample sorts including self-collected capillary blood, saliva and nasal swabs.
“The want for precise and dependable screening in response to the worldwide COVID-19 pandemic continues, and we are honored to have been picked by the NIH to progress to Phase 2 of this essential initiative,” explained Kevin Hrusovsky, Chairman, Chief Govt Officer and President, Quanterix and Founder, Powering Precision Overall health (PPH).
Initial early feasibility of the examination was funded in component as a result of a RADx Period 1 award. The Period 2 agreement supports scientific validation of the take a look at in support of planned crisis use authorization (EUA) submissions with the U.S. Food and Drug Administration. The agreement provides funding to broaden assay kit manufacturing capability at the Company’s Billerica, Massachusetts facility and business deployment readiness. Making use of the Company’s significant-throughput automated Hd-X instrument platform, Quanterix intends to make the examination obtainable by way of a network of centralized 3rd-party labs. Agreement funding is issue to achievement of pre-outlined milestones and the contract interval runs by September 2021.
“We think our technology, combined with the help of the NIH and the strength of our partnerships throughout the Powering Precision Wellbeing ecosystem, will assist guidance the accelerated development and scaling of critical screening essential to enable earn the struggle towards COVID-19,” ongoing Hrusovsky. “These investments guidance and complement developments we are creating with special and hugely delicate assay capabilities and technological know-how in neurology, oncology and HIV. We glimpse ahead to accelerating our impact by making use of these strengths toward COVID-19.”
This task has been funded in component by the RADx℠ initiative with federal resources from the National Institute of Biomedical Imaging and Bioengineering, Nationwide Institutes of Overall health. The present agreement is funded from the General public Well being and Social Solutions Emergency Fund by the Biomedical State-of-the-art Investigate and Advancement Authority, HHS Workplace of the Assistant Secretary for Preparedness and Reaction, Office of Health and fitness and Human Providers.
For extra information and facts on Quanterix’ Simoa technological innovation, visit https://www.quanterix.com/engineering. To find out a lot more about Quanterix’ infectious disease investigate and RUO assay improvement options, go to https://www.quanterix.com/therapeutic-places/infectious-illness.
About Quanterix
Quanterix is a enterprise which is digitizing biomarker evaluation with the goal of advancing the science of precision wellbeing. The company’s digital overall health resolution, Simoa®, has the probable to modify the way in which health care is furnished now by supplying researchers the capability to carefully look at the continuum from wellbeing to ailment. Quanterix’ technological know-how is created to allow substantially previously disease detection, greater prognoses and improved treatment techniques to make improvements to the excellent of life and longevity of the inhabitants for generations to occur. The engineering is at this time remaining used for research purposes in several therapeutic spots, including oncology, neurology, cardiology, inflammation and infectious ailment. The enterprise was proven in 2007 and is located in Billerica, Massachusetts. For more information and facts, you should go to https://www.quanterix.com.
Forward-Looking Statements
This press launch includes forward-on the lookout statements within just the that means of the Personal Securities Litigation Reform Act of 1995. Words and phrases this sort of as “might,” “will,” “anticipate,” “system,” “anticipate,” “estimate,” “intend” and similar expressions (as perfectly as other terms or expressions referencing long run situations, problems or circumstances) are supposed to discover ahead-searching statements. Forward-hunting statements in this information release are dependent on Quanterix’ expectations and assumptions as of the date of this press release. Every of these ahead-seeking statements will involve dangers and uncertainties. Components that could trigger Quanterix’ actual outcomes to differ from these expressed or implied in the forward-wanting statements in this push release are mentioned in Quanterix’ filings with the U.S. Securities and Trade Fee, together with the “Chance Variables” sections contained therein. Apart from as needed by legislation, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any transform in anticipations, even as new information will become obtainable.
Check out resource variation on businesswire.com: https://www.businesswire.com/information/property/20201006006039/en/
Contacts
Media Contact:
PAN Communications
Staci Didner, (407) 734-7325
[email protected]
Trader Relations Make contact with:
Stephen Hrusovsky
(774) 278-0496
[email protected]